Cellular immunotherapy for malignant gliomas

References

• Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol. 2015 Oct;17 Suppl 4:iv1–iv62. doi:10.1093/neuonc/nov189.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996. doi:10.1056/NEJMoa043330.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug 19;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015 Jan 22;372(4):320–330.
   PubMed Web of Science ®Google Scholar
• Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014 Sep 20;384(9948):1109–1117.
   PubMed Web of Science ®Google Scholar
• Sundar R, Cho BC, Brahmer JR, et al. Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2015 Mar;7(2):85–96. doi:10.1177/1758834014567470.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010 Jul 29;363(5):411–422.
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014 Oct 16;371(16):1507–1517.
   PubMed Web of Science ®Google Scholar
• Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013 Apr 18;368(16):1509–1518.
   PubMed Web of Science ®Google Scholar
• Dilloo D, Bacon K, Holden W, et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat Med. 1996 Oct;2(10):1090–1095.
   PubMed Web of Science ®Google Scholar
• Okada H, Lieberman FS, Walter KA, et al. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Transl Med. 2007;5:67. doi:10.1186/1479-5876-5-67.
   PubMed Web of Science ®Google Scholar
• Kusumoto M, Umeda S, Ikubo A, et al. Phase 1 clinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF gene. Cancer Immunol Immunother. 2001 Sep;50(7):373–381.
   PubMed Web of Science ®Google Scholar
• Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993 Apr 15;90(8):3539–3543.
   PubMed Web of Science ®Google Scholar
• Dols A, Smith JW 2nd, Meijer SL, et al. Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results. Hum Gene Ther. 2003 Jul 20;14(11):1117–1123.
   PubMed Web of Science ®Google Scholar
• Okada H, Giezeman-Smits KM, Tahara H, et al. Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSVtk tumor vaccine. Gene Ther. 1999 Feb;6(2):219–226. doi:10.1038/sj.gt.3300798.
   PubMed Web of Science ®Google Scholar
• Okada H, Villa L, Attanucci J, et al. Cytokine gene therapy of gliomas: effective induction of therapeutic immunity to intracranial tumors by peripheral immunization with interleukin-4 transduced glioma cells. Gene Ther. 2001 Aug;8(15):1157–1166. doi:10.1038/sj.gt.3301496.
   PubMed Web of Science ®Google Scholar
• Eguchi J, Hiroishi K, Ishii S, et al. Interleukin-4 gene transduced tumor cells promote a potent tumor-specific Th1-type response in cooperation with interferon-alpha transduction. GeneTher. 2005;12:733–741.
   Google Scholar
• Kuwashima N, Nishimura F, Eguchi J, et al. Delivery of dendritic cells engineered to secrete IFN-{alpha} into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways. J Immunol. 2005;175(4):2730–2740. doi:10.4049/jimmunol.175.4.2730.
   PubMed Web of Science ®Google Scholar
• Ishikawa E, Muragaki Y, Yamamoto T, et al. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma. J Neurosurg. 2014 Sep;121(3):543–553. doi:10.3171/2014.5.JNS132392.
   PubMed Web of Science ®Google Scholar
• Curry WT Jr., Gorrepati R, Piesche M, et al. Vaccination with irradiated autologous tumor cells mixed with irradiated GM-K562 cells stimulates antitumor immunity and T lymphocyte activation in patients with recurrent malignant glioma. Clin Cancer Res. 2016 Feb 12;22:2885–2896. doi:10.1158/1078-0432.CCR-15-2163.
   PubMed Web of Science ®Google Scholar
• Kalinski P, Edington H, Zeh HJ, et al. Dendritic cells in cancer immunotherapy: vaccines or autologous transplants? Immunol Res. 2011 Aug;50(2–3):235–247. doi:10.1007/s12026-011-8224-z.
   PubMed Web of Science ®Google Scholar
• Ajay D, Sanchez-Perez L, Choi BD, et al. Immunotherapy with tumor vaccines for the treatment of malignant gliomas. Curr Drug Discov Technol. 2012 Dec;9(4):237–255.
   PubMedGoogle Scholar
• De Vleeschouwer S, Van Gool SW, Van Calenbergh F. Immunotherapy for malignant gliomas: emphasis on strategies of active specific immunotherapy using autologous dendritic cells. Childs Nerv Syst. 2005 Jan;21(1):7–18. doi:10.1007/s00381-004-0994-3.
   PubMed Web of Science ®Google Scholar
• Liau LM, Black KL, Martin NA, et al. Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report Neurosurg Focus. 2000;9(6):e8.
   PubMedGoogle Scholar
• Yu JS, Wheeler CJ, Zeltzer PM, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. 2001 Feb 1;61(3):842–847.
   PubMed Web of Science ®Google Scholar
• Wheeler CJ, Black KL, Liu G, et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res. 2008 Jul 15;68(14):5955–5964.
   PubMed Web of Science ®Google Scholar
• Ardon H, Van Gool SW, Verschuere T, et al. Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial. Cancer Immunol Immunother. 2012 Nov;61(11):2033–2044. doi:10.1007/s00262-012-1261-1.
   PubMed Web of Science ®Google Scholar
• Prins RM, Soto H, Konkankit V, et al. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res. 2011 Mar 15;17(6):1603–1615.
   PubMed Web of Science ®Google Scholar
• Okada H. Brain tumor immunotherapy with type-1 polarizing strategies. Ann NY Acad Sci. 2009 Sep;1174:18–23. doi:10.1111/j.1749-6632.2009.04932.x.
   PubMed Web of Science ®Google Scholar
• Sampson JH, Mitchell DA. Vaccination strategies for neuro-oncology. Neuro Oncol. 2015 Nov;17 Suppl 7:vii15–vii25. doi:10.1093/neuonc/nov159.
   PubMed Web of Science ®Google Scholar
• Reardon DA, Freeman G, Wu C, et al. Immunotherapy advances for glioblastoma. Neuro-oncology. 2014 Nov;16(11):1441–1458. doi:10.1093/neuonc/nou212.
   PubMed Web of Science ®Google Scholar
• Reardon DA, Wucherpfennig KW, Freeman G, et al. An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines. 2013 Jun;12(6):597–615. doi:10.1586/erv.13.41.
   PubMed Web of Science ®Google Scholar
• Okada H, Kalinski P, Ueda R, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol. 2011 January 20;29(3):330–336.
   PubMed Web of Science ®Google Scholar
• Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother. 2013 Jan;62(1):125–135. doi:10.1007/s00262-012-1319-0.
   PubMed Web of Science ®Google Scholar
• Slingluff CL Jr., Petroni GR, Yamshchikov GV, et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol. 2003 Nov 1;21(21):4016–4026.
   PubMed Web of Science ®Google Scholar
• Wheeler CJ, Das A, Liu G, et al. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res. 2004 Aug 15;10(16):5316–5326.
   PubMed Web of Science ®Google Scholar
• Bloch O, Crane CA, Fuks Y, et al. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol. 2014 Jan;16(2):274–279. doi:10.1093/neuonc/not203.
   PubMed Web of Science ®Google Scholar
• Litterman AJ, Zellmer DM, Grinnen KL, et al. Profound impairment of adaptive immune responses by alkylating chemotherapy. J Immunology. 2013 Jun 15;190(12):6259–6268. doi:10.4049/jimmunol.1203539.
   PubMed Web of Science ®Google Scholar
• Dziurzynski K, Chang SM, Heimberger AB, et al. Consensus on the role of human cytomegalovirus in glioblastoma. Neuro Oncol. 2012 March 1;14(3):246–255.
   PubMed Web of Science ®Google Scholar
• Cobbs CS, Harkins L, Samanta M, et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 2002;62(12):3347–3350.
   PubMed Web of Science ®Google Scholar
• Mitchell DA, Batich KA, Gunn MD, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature. 2015 Mar 19;519(7543):366–369. doi:10.1038/nature14320.
   PubMed Web of Science ®Google Scholar
• Merchant RE, Ellison MD, Young HF. Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of pre-clinical and clinical investigations. J Neurooncol. 1990 Apr;8(2):173–188.
   PubMed Web of Science ®Google Scholar
• Ishikawa E, Takano S, Ohno T, et al. Adoptive cell transfer therapy for malignant gliomas. Adv Exp Med Biol. 2012;746:109–120. doi:10.1007/978-1-4614-3146-6_9.
   PubMed Web of Science ®Google Scholar
• Law TM, Motzer RJ, Mazumdar M, et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer. 1995 Sep 1;76(5):824–832.
   PubMed Web of Science ®Google Scholar
• Fujisaki H, Kakuda H, Shimasaki N, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 2009 May 1;69(9):4010–4017.
   PubMed Web of Science ®Google Scholar
• Barkholt L, Alici E, Conrad R, et al. Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study. Immunotherapy. 2009 Sep;1(5):753–764. doi:10.2217/imt.09.47.
   PubMed Web of Science ®Google Scholar
• Rezvani K, Rouce RH. The application of natural killer cell immunotherapy for the treatment of cancer. Front Immunol. 2015;6:578. doi:10.3389/fimmu.2015.00578.
   PubMed Web of Science ®Google Scholar
• Groh V, Porcelli S, Fabbi M, et al. Human lymphocytes bearing T cell receptor gamma/delta are phenotypically diverse and evenly distributed throughout the lymphoid system. J Exp Med. 1989 Apr 1;169(4):1277–1294.
   PubMed Web of Science ®Google Scholar
• von Lilienfeld-Toal M, Nattermann J, Feldmann G, et al. Activated gammadelta T cells express the natural cytotoxicity receptor natural killer p 44 and show cytotoxic activity against myeloma cells. Clin Exp Immunol. 2006 Jun;144(3):528–533. doi:10.1111/j.1365-2249.2006.03078.x.
   PubMed Web of Science ®Google Scholar
• Girardi M, Oppenheim DE, Steele CR, et al. Regulation of cutaneous malignancy by gammadelta T cells. Science. 2001 Oct 19;294(5542):605–609.
   PubMed Web of Science ®Google Scholar
• Deniger DC, Maiti SN, Mi T, et al. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies. Clin Cancer Res. 2014 Nov 15;20(22):5708–5719.
   PubMed Web of Science ®Google Scholar
• Nicol AJ, Tokuyama H, Mattarollo SR, et al. Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours. Br J Cancer. 2011 Sep 6;105(6):778–786.
   PubMed Web of Science ®Google Scholar
• Lamb LS Jr. Gammadelta T cells as immune effectors against high-grade gliomas. Immunol Res. 2009;45(1):85–95. doi:10.1007/s12026-009-8114-9.
   PubMed Web of Science ®Google Scholar
• Bryant NL, Gillespie GY, Lopez RD, et al. Preclinical evaluation of ex vivo expanded/activated gammadelta T cells for immunotherapy of glioblastoma multiforme. J Neurooncol. 2011 Jan;101(2):179–188. doi:10.1007/s11060-010-0245-2.
   PubMed Web of Science ®Google Scholar
• Pereboeva L, Harkins L, Wong S, et al. The safety of allogeneic innate lymphocyte therapy for glioma patients with prior cranial irradiation. Cancer Immunol Immunother. 2015 May;64(5):551–562. doi:10.1007/s00262-015-1662-z.
   PubMed Web of Science ®Google Scholar
• Lamb LS Jr., Bowersock J, Dasgupta A, et al. Engineered drug resistant gammadelta T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy. PLoS One. 2013;8(1):e51805. doi:10.1371/journal.pone.0051805.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015 Apr 3;348(6230):62–68. doi:10.1126/science.aaa4967.
   PubMed Web of Science ®Google Scholar
• Saris SC, Spiess P, Lieberman DM, et al. Treatment of murine primary brain tumors with systemic interleukin-2 and tumor-infiltrating lymphocytes. J Neurosurg. 1992 Mar;76(3):513–519. doi:10.3171/jns.1992.76.3.0513.
   PubMed Web of Science ®Google Scholar
• Quattrocchi KB, Miller CH, Cush S, et al. Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J Neurooncol. 1999;45(2):141–157.
   PubMed Web of Science ®Google Scholar
• Glitza IC, Haymaker C, Bernatchez C, et al. Intrathecal administration of tumor-infiltrating lymphocytes is well tolerated in a patient with leptomeningeal disease from metastatic melanoma: a case report. Cancer Immunol Res. 2015 Nov;3(11):1201–1206. doi:10.1158/2326-6066.CIR-15-0071.
   PubMed Web of Science ®Google Scholar
• Balch CM, Riley LB, Bae YJ, et al. Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. Arch Surg. 1990 Feb;125(2):200–205.
   PubMed Web of Science ®Google Scholar
• Plautz GE, Barnett GH, Miller DW, et al. Systemic T cell adoptive immunotherapy of malignant gliomas. J Neurosurg. 1998 Jul;89(1):42–51. doi:10.3171/jns.1998.89.1.0042.
   PubMed Web of Science ®Google Scholar
• Plautz GE, Miller DW, Barnett GH, et al. T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res. 2000 Jun;6(6):2209–2218.
   PubMed Web of Science ®Google Scholar
• Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314(5796):126–129. doi:10.1126/science.1129003.
   PubMed Web of Science ®Google Scholar
• Stanislawski T, Voss RH, Lotz C, et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol. 2001 Oct;2(10):962–970. doi:10.1038/ni1001-962.
   PubMed Web of Science ®Google Scholar
• Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009 Jul 16;114(3):535–546.
   PubMed Web of Science ®Google Scholar
• Xue SA, Gao L, Thomas S, et al. Development of a Wilms’ tumor antigen-specific T-cell receptor for clinical trials: engineered patient’s T cells can eliminate autologous leukemia blasts in NOD/SCID mice. Haematologica. 2010 Jan;95(1):126–134. doi:10.3324/haematol.2009.006486.
   PubMed Web of Science ®Google Scholar
• Okamoto S, Mineno J, Ikeda H, et al. Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR. Cancer Res. 2009 Dec 1;69(23):9003–9011.
   PubMed Web of Science ®Google Scholar
• Govers C, Sebestyen Z, Coccoris M, et al. T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing. Trends Mol Med. 2010 Feb;16(2):77–87. doi:10.1016/j.molmed.2009.12.004.
   PubMed Web of Science ®Google Scholar
• Zhang L, Morgan RA. Genetic engineering with T cell receptors. Adv Drug Deliv Rev. 2012 Jun 1;64(8):756–762.
   PubMed Web of Science ®Google Scholar
• Parkhurst MR, Yang JC, Langan RC, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 2011 Mar;19(3):620–626. doi:10.1038/mt.2010.272.
   PubMed Web of Science ®Google Scholar
• Morgan RA, Chinnasamy N, Abate-Daga D, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunotherapy. 2013 Feb;36(2):133–151. doi:10.1097/CJI.0b013e3182829903.
   PubMed Web of Science ®Google Scholar
• Robbins PF, Kassim SH, Tran TL, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 2015 Mar 1;21(5):1019–1027.
   PubMed Web of Science ®Google Scholar
• Rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med. 2015 Aug;21(8):914–921. doi:10.1038/nm.3910.
   PubMed Web of Science ®Google Scholar
• Ngo MC, Rooney CM, Howard JM, et al. Ex vivo gene transfer for improved adoptive immunotherapy of cancer. Hum Mol Genet. 2011 April 15;20(R1):R93–R99.
   PubMedGoogle Scholar
• Moeller M, Haynes NM, Trapani JA, et al. A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells. Cancer Gene Ther. 2004;11(5):371–379. doi:10.1038/sj.cgt.7700710.
   PubMed Web of Science ®Google Scholar
• Beckman RA, Weiner LM, Davis HM. Antibody constructs in cancer therapy - protein engineering strategies to improve exposure in solid tumors. Cancer. 2007 Jan;109(2):170–179. doi:10.1002/cncr.22402.
   PubMed Web of Science ®Google Scholar
• Weijtens M, Willemsen R, Valerio D, et al. Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. J Immunol. 1996 July 15;157(2):836–843.
   PubMed Web of Science ®Google Scholar
• Maus MV, June CH. Making better chimeric antigen receptors for adoptive T-cell therapy. Clin Cancer Res. 2016 Apr 15;22(8):1875–1884.
   PubMed Web of Science ®Google Scholar
• Kahlon KS, Brown C, Cooper LJ, et al. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res. 2004 Dec 15;64(24):9160–9166.
   PubMed Web of Science ®Google Scholar
• Ahmed N, Salsman VS, Kew Y, et al. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res. 2010 Jan 15;16(2):474–485.
   PubMed Web of Science ®Google Scholar
• Chow KK, Naik S, Kakarla S, et al. T cells redirected to EphA2 for the immunotherapy of glioblastoma. Mol Ther. 2013 Mar;21(3):629–637. doi:10.1038/mt.2012.210.
   PubMed Web of Science ®Google Scholar
• Ohno M, Ohkuri T, Kosaka A, et al. Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts. J Immunother Cancer. 2013;1:21. doi:10.1186/2051-1426-1-21.
   PubMedGoogle Scholar
• Johnson LA, Scholler J, Ohkuri T, et al. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med. 2015 Feb 18;7(275):275ra22.
   PubMed Web of Science ®Google Scholar
• Bullain SS, Sahin A, Szentirmai O, et al. Genetically engineered T cells to target EGFRvIII expressing glioblastoma. J Neurooncol. 2009 Sep;94(3):373–382. doi:10.1007/s11060-009-9889-1.
   PubMed Web of Science ®Google Scholar
• Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843–851. doi:10.1038/mt.2010.24.
   PubMed Web of Science ®Google Scholar
• Brown CE, Badie B, Barish ME, et al. Bioactivity and safety of IL13Ralpha2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin Cancer Res. 2015 Sep 15;21(18):4062–4072.
   PubMed Web of Science ®Google Scholar
• Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008 Nov;14(11):1264–1270. doi:10.1038/nm.1882.
   PubMed Web of Science ®Google Scholar
• Hegde M, Corder A, Chow KK, et al. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther. 2013 Nov;21(11):2087–2101. doi:10.1038/mt.2013.185.
   PubMed Web of Science ®Google Scholar
• Kloss CC, Condomines M, Cartellieri M, et al. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol. 2013 Jan;31(1):71–75. doi:10.1038/nbt.2459.
   PubMed Web of Science ®Google Scholar
• Wilkie S, Van Schalkwyk MC, Hobbs S, et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol. 2012 Oct;32(5):1059–1070. doi:10.1007/s10875-012-9689-9.
   PubMed Web of Science ®Google Scholar
• Grada Z, Hegde M, Byrd T, et al. TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol Ther Nucleic Acids. 2013;2:e105. doi:10.1038/mtna.2013.32.
   PubMedGoogle Scholar
• Minagawa K, Zhou X, Mineishi S, et al. Seatbelts in CAR therapy: how safe are CARS? Pharmaceuticals (Basel). 2015;8(2):230–249. doi:10.3390/ph8020230.
   PubMedGoogle Scholar
• Roybal KT, Rupp LJ, Morsut L, et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell. 2016 Feb 11;164(4):770–779.
   PubMed Web of Science ®Google Scholar
• Schumacher T, Bunse L, Pusch S, et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature. 2014 Jun 25;512:324–327. doi:10.1038/nature13387.
   PubMed Web of Science ®Google Scholar
• Cameron BJ, Gerry AB, Dukes J, et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med. 2013 Aug 7;5(197):197ra03.
   Web of Science ®Google Scholar
• Sampson JH, Heimberger AB, Archer GE, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010 Nov 1;28(31):4722–4729.
   PubMed Web of Science ®Google Scholar
• Kohanbash G, Okada H. Myeloid-derived suppressor cells in gliomas and glioma-development. Immunol Invest. 2012;41(6–7):658–679. doi:10.3109/08820139.2012.689591.
   PubMed Web of Science ®Google Scholar
• Okada H, Butterfield LH, Hamilton RL, et al. Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with Poly-ICLC. Clin Cancer Res. 2015 Jan 15;21(2):286–294.
   PubMed Web of Science ®Google Scholar
• Okada H, Tsugawa T, Sato H, et al. Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines. Cancer Res. 2004;64(16):5830–5838. doi:10.1158/0008-5472.CAN-04-0130.
   PubMed Web of Science ®Google Scholar
• Pollack IF, Jakacki RI, Butterfield LH, et al. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. J Clin Oncol. 2014 Jul 1;32(19):2050–2058.
   PubMed Web of Science ®Google Scholar
• Kershaw MH, Wang G, Westwood JA, et al. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther. 2002 Nov 1;13(16):1971–1980.
   PubMed Web of Science ®Google Scholar
• Di Stasi A, De Angelis B, Rooney CM, et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009 Jun 18;113(25):6392–6402.
   PubMed Web of Science ®Google Scholar
• Craddock JA, Lu A, Bear A, et al. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother. 2010 Oct;33(8):780–788. doi:10.1097/CJI.0b013e3181ee6675.
   PubMed Web of Science ®Google Scholar
• Moon EK, Carpenito C, Sun J, et al. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res. 2011 Jul 15;17(14):4719–4730.
   PubMed Web of Science ®Google Scholar
• Grossman SA, Ye X, Lesser G, et al. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res. 2011 Aug 15;17(16):5473–5480.
   PubMed Web of Science ®Google Scholar
• Chmielewski M, Abken H. TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther. 2015;15(8):1145–1154. doi:10.1517/14712598.2015.1046430.
   PubMed Web of Science ®Google Scholar
• Kerkar SP, Muranski P, Kaiser A, et al. Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res. 2010 Sep 1;70(17):6725–6734.
   PubMed Web of Science ®Google Scholar
• Zhang L, Kerkar SP, Yu Z, et al. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther. 2011 Apr;19(4):751–759. doi:10.1038/mt.2010.313.
   PubMed Web of Science ®Google Scholar
• Chmielewski M, Kopecky C, Hombach AA, et al. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 2011 Sep 1;71(17):5697–5706.
   PubMed Web of Science ®Google Scholar
• Bollard CM, Rossig C, Calonge MJ, et al. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood. 2002 May 1;99(9):3179–3187.
   PubMed Web of Science ®Google Scholar
• Abate-Daga D, Hanada K, Davis JL, et al. Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes. Blood. 2013 Aug 22;122(8):1399–1410.
   PubMed Web of Science ®Google Scholar
• John LB, Devaud C, Duong CP, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res. 2013 Oct 15;19(20):5636–5646.
   PubMed Web of Science ®Google Scholar
• John LB, Kershaw MH, Darcy PK. Blockade of PD-1 immunosuppression boosts CAR T-cell therapy. Oncoimmunology. 2013 Oct 1;2(10):e26286.
   PubMed Web of Science ®Google Scholar
• Okada H, Pollack IF. Do we need novel radiologic response criteria for brain tumor immunotherapy? Expert Rev Neurother. 2011;11(5):619–622. doi:10.1586/ern.11.49.
   PubMed Web of Science ®Google Scholar
• Okada H, Weller M, Huang R, et al. immunotherapy Response Assessment in Neuro-Oncology (iRANO): a report of the RANO working group. Lancet Oncol. 2015;15:534–542. doi:10.1016/S1470-2045(15)00088-1.
   Google Scholar
• Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009 Dec 1;15(23):7412–7420.
   PubMed Web of Science ®Google Scholar
• Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010 April 10;28(11):1963–1972.
   PubMed Web of Science ®Google Scholar